AptaBio Therapeutics Inc - Asset Resilience Ratio

Latest as of September 2025: 1.57%

AptaBio Therapeutics Inc (293780) has an Asset Resilience Ratio of 1.57% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 293780 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩1.05 Billion
≈ $712.80K USD Cash + Short-term Investments

Total Assets

₩67.12 Billion
≈ $45.49 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how AptaBio Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see AptaBio Therapeutics Inc asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down AptaBio Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does AptaBio Therapeutics Inc carry for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩1.05 Billion 1.57%
Total Liquid Assets ₩1.05 Billion 1.57%

Asset Resilience Insights

  • Limited Liquidity: AptaBio Therapeutics Inc maintains only 1.57% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

AptaBio Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare AptaBio Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 0.50%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 5.50%
Neuland Laboratories Limited
NSE:NEULANDLAB
Drug Manufacturers - Specialty & Generic 9.65%
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
Drug Manufacturers - Specialty & Generic 1.18%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.01%

Annual Asset Resilience Ratio for AptaBio Therapeutics Inc (2017–2024)

The table below shows the annual Asset Resilience Ratio data for AptaBio Therapeutics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 7.71% ₩5.97 Billion
≈ $4.05 Million
₩77.43 Billion
≈ $52.48 Million
-22.41pp
2023-12-31 30.12% ₩27.87 Billion
≈ $18.89 Million
₩92.52 Billion
≈ $62.70 Million
+3.34pp
2022-12-31 26.78% ₩15.03 Billion
≈ $10.18 Million
₩56.11 Billion
≈ $38.03 Million
-8.52pp
2021-12-31 35.30% ₩22.91 Billion
≈ $15.53 Million
₩64.91 Billion
≈ $43.99 Million
-21.47pp
2020-12-31 56.76% ₩42.82 Billion
≈ $29.02 Million
₩75.44 Billion
≈ $51.13 Million
-2.87pp
2019-12-31 59.63% ₩46.16 Billion
≈ $31.28 Million
₩77.40 Billion
≈ $52.46 Million
-37.25pp
2018-12-31 96.88% ₩19.69 Billion
≈ $13.35 Million
₩20.33 Billion
≈ $13.78 Million
+0.80pp
2017-12-31 96.08% ₩10.57 Billion
≈ $7.16 Million
₩11.00 Billion
≈ $7.46 Million
--
pp = percentage points

About AptaBio Therapeutics Inc

KQ:293780 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$114.59 Million
₩169.08 Billion KRW
Market Cap Rank
#18757 Global
#871 in Korea
Share Price
₩6290.00
Change (1 day)
-1.72%
52-Week Range
₩4000.00 - ₩10420.00
All Time High
₩61500.00
About

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing n… Read more